The thiopurine drugs, azathioprine (AZA) and 6-mercaptopurine, are established in the treatment of infl ammatory bowel diseases (IBD). Polymorphisms in thiopurine S-methyltransferase (TPMT) gene have been associated with adverse drug reactions (ADRs) to AZA. Methods: The aim of this study was to evaluate TPMT polymorphisms and AZA-related toxicity in a Slovak cohort of 220 IBD patients treated with AZA. In every patient, the dose and duration of AZA therapy, concomitant 5-aminosalicylate (5-ASA) medication, frequency, type, time to onset, dose of ADR and concomitant 5-ASA at the onset of ADR were recorded. Each patient was also genotyped for the presence of variant TPMT alleles (*2,*3A,*3B,*3C). Frequency, type and circumstances of ADRs were compared according to TPMT status. Results: Of the 220 patients, 205 (93.2 %) were wild-type (TPMT*1/*1), one (0.5%) carried a TPMT*1/*3C allele, 13 (5.9 %) carried TPMT *1/*3A allele and one was homozygous for TMPT *3A allele. No TPMT *2 mutation was found. The incidence of adverse drug reactions was 62/205 (30.2 %) in the wild-type group as compared to 13/15 (86.7 %) in the TPMT mutation group, p=2.10 -5 . Leukopenia (WBC< 3.0*10^9/L) occurred in 21/205 (10.2 %) patients with wild type TPMT versus 11/15 (73.3 %) patients with TPMT mutations, p=0.000001. There was no signifi cant difference between TMPT groups in gastrointestinal or other ADRs. No impact of 5-ASA on the incidence and severity of AZA adverse drug reactions was observed.
Abbreviations used: 5-ASA -5-aminosalicylic acid, 6-MP -6-mercaptopurine, ADR -adverse drug reaction, AZA -azathioprine, CD -Crohn's disease, IBD -infl ammatory bowel disease, TPMT -thiopurine-S-methyltransferase, UC -ulcerative colitis.
Infl ammatory bowel diseases (IBD) are a group of chronic relapsing infl ammatory diseases comprising Crohn's disease (CD), ulcerative colitis (UC) and indeterminate colitis. The thiopurine drugs azathioprine (AZA) and 6-mercaptopurine (6-MP) have been shown to be an effective therapy for inducing and maintaining remission in both Crohn's disease and ulcerative colitis (1) (2) (3) (4) (5) (6) . Adverse drug reactions occur in 15-30 % of patients and often require dose reduction or drug discontinuation (7) (8) (9) . The most often adverse drug reactions are nausea/dyspepsia, bone marrow suppression, hepatic toxicity, pancreatitis and allergic reactions. The most severe side effect, observed in up to 10 % of patients, is the bone marrow suppression with neutropenia and /or pancytopenia, which can be lethal. Generally it is a dose-related adverse drug reaction; however there is a signifi cant inter-individual variability, mostly due to polymorphisms in genes encoding the metabolic pathways of thiopurines.
There are three major metabolic pathways of thiopurines mediated by enzymes hypoxantine phosphoribosyl transferase (HPRT), thiopurine-S-methyltransferase (TPMT) and xantine oxidase (XO). The intracellular formation of active substances is mediated by HPRT and results in the formation of thioguanine nucleotides (TGN). They are purine antagonists and exert cytotoxic and immunosuppressive effects partially by direct incorporation of TGN into DNA with subsequent inhibition of DNA, RNA and protein synthesis (10) . It has been also shown that TGN induce lymphocyte apoptosis through replacing guanine triphosphate and subsequent suppression of Rac1 activity (11) . Selective inhibition of infl ammatory genes expression in activated T lymphocytes is another observed mechanism of action of thiopurines (12) .
Methylation and oxidative metabolic pathways mediated by TPMT and XO compete with the HPRT-mediated formation of TGNs. The methylation of 6-MP metabolite thioinosine monophosphate (TIMP) by TPMT leads to the production of methylthiosine monophosphate (meTIMP) which is a potent inhibitor of purine de novo synthesis (13, 14) . High meTIMP levels are also associated with an increased risk of hepatotoxicity (15, 16) . There are several known polymorphisms in TPMT gene associated with a decrease in TPMT activity and myelotoxicity due to high TGN metabolite concentrations (17, 18) .
In our retrospective study we wanted to analyze the association of major TPMT polymorphisms and various adverse drug reactions in a large cohort of IBD patients treated with AZA. Specifi cally we were interested in the interaction of TPMT genotype with the dose, concomitant 5-ASA medication and time to onset of the adverse drug reactions.
Materials and methods

Patient cohort
The patient cohort consisted of 220 consecutive IBD patients who were treated with AZA or 6-MP either currently or in the past. The patients were recruited from six participating IBD centers from the Slovak IBD study group (SK-IBD) between January 1, 2009 and May 31, 2009. All eligible patients who signed the informed consent for the genetic examination of TPMT polymorphisms and agreed to participate in the study were included. No other genetic test has been or will be done on biological material obtained in this study unless explicitly consented to and signed by the patient.
Clinical characteristics of each patient including sex, age, current and previous azathioprine medication, start and duration of AZA therapy, current 5-aminosalycilic acid (5-ASA) therapy and dose, current blood count, CRP and creatinine levels were collected.
Adverse drug reactions to azathioprine therapy
Medical records of every patient were screened for the history of adverse drug reactions (ADR) to azathioprine therapy. In most patients a detailed history including medical and laboratory data was readily available in his/her physical and/or electronic patient data fi le. In patients referred to participating centers, the referring physician was contacted and consulted if necessary. In case of an adverse drug reaction, the date of the adverse drug reaction, duration of AZA therapy before the adverse drug reaction, the dose of AZA, concomitant 5-aminosalycilic acid (5-ASA) therapy and its dose, blood count, creatinine and C-reactive protein (CRP) levels were recorded.
Leukopenia was defi ned as a white blood cells count (WBC) <3.0x10 9 /ml. Anemia was considered AZA-related if developed quickly during AZA therapy in absence of apparent bleeding, hemoglobine levels decreased below 100g/L and reversed to normal after AZA cessation or dose reduction. Trombocytopenia was defi ned as platelets count <100x10 9 /L. Hepatotoxicity was defi ned as an elevation of alanine transaminase (ALT) or aspartate aminotransferase (AST) levels of at least twice the upper limit of normal. Pancreatitis was defi ned as an elevation of serum amylase or lipase of more than twice the upper limit of normal, associated with abdominal pain. The diagnosis of allergic reaction, dyspepsia and other adverse drug reactions was made by the clinician, who treated the respective patient.
TPMT polymorphism genotyping
Total genomic DNA was extracted from peripheral blood cells using the Puregene Blood Core kit (Qiagen, Hilden, Germany). PCR method was used for preamplifi cation of three fragments containing polymorphisms in TPMT gene. The 279-bp fragment containing the polymorphism A719G was amplifi ed with primers A719G-F (5´-CACCCAGCCAATTTTGAGTAT-3´) and A719G-R (5´-TCCATTACATTTTCAGGCTTTAG-3´). The 398-bp fragment containing the polymorphism G460A was amplifi ed with primers G460A-F (5´-AAACGCAGACGTGAGATCCT-3´) and G460A-R (5´-GCCTTACACCCAGGTCTCTG-3´). The 252-bp fragment containing the polymorphism G238C was amplifi ed with primers G238C-F (5´-GCATGTTCTTTGAAACCCTATGA-3´) and G238C-R (5´-GGAATTTCGGTGATTGGTTC-3´). Amplifi cations were performed in a 10 μl reaction volume containing 50 ng of genomic DNA, 1x concentrated 5PRIME HotMasterMix (5PRIME, Hamburg, Germany) and 2.5 pmol of each primer. The amplifi cations were performed on TC-412 thermocycler (TECHNE, Bibby Scientifi c, Stone, UK). Samples were denatured at 95 °C for 4 minutes, followed by 30 cycles at 95 °C for 40 seconds, 58 °C for 30 seconds, and 72 °C for 40 seconds. Amplifi cation cycles were followed by a ten-minute fi nal extension at 72 °C. These fragments were then used as a template for sequencing reactions. For sequence analysis of samples, BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Carlsbad, CA, USA) and the ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems,, Carlsbad, CA, USA) instrument was used. Obtained sequences were analyzed by Sequencing Analysis Software v 5.4 (Applied Biosystems, Carlsbad, CA, USA) and Chromas Lite v 2.01 (Technelysium Pty Ltd, Australia) and subsequently compared to GenBank reference sequences using BLAST sequence alignment software (http://blast.ncbi.nlm.nih.gov/genbank).
Statistical analysis
All statistical analyses were performed using SPSS 18.0 statistical software package (IBM SPSS Inc., Chicago, IL, USA). Nominal and ordinal variables (sex, current AZA use, genotype, adverse drug reactions) were analyzed with Chi square test with Yates correction. If any cell of the contingency table contained a value of less than 5, Fisher exact test was used instead. For each statistically positive result, an odds ratio (OR) with 95% confi dence intervals (CI) was calculated. Continuous variables (age, duration of AZA use, laboratory results) were fi rst analyzed for normality with Kolmogorow-Smirnoff test and then tested by the Student t-test or ANOVA techniques as appropriate. The distribution of alleles was tested with equilibrium analysis. P value < 0.05 was considered statistically signifi cant.
Results
The cohort consisted of 220 patients. All used azathioprine; there was no 6-MP use among the patients in our cohort. The clinical characteristics of the cohort as well as the comparison between the current and past AZA users are given in Table 1 .
All patients were successfully genotyped for the studied TPMT polymorphisms. A total of 205 (93.2 %) patients carried a normal TPMT *1/*1 genotype. There was no patient with TPMT *2 allele. In 15 patients (6.8 %) a TPMT *3 mutation was diagnosed. There were 13 patients (5.9 %) with TPMT *1/*3A heterozygote genotype, 1 patient (0.4 %) with TPMT *1/*3C heterozygote genotype, and one patient homozygous for TPMT *3A genotype (0.4 %).
Adverse drug reactions to azathioprine therapy A total of 75 (34.1 %) patients experienced some type of adverse drug reactions during the course of azathioprine therapy. The most frequent adverse drug reactions were myelotoxicity (in 32; 14.5 %) and hepatotoxicity (in 24; 10.9 %) of patients. The overview of frequency of adverse drug reaction is given in Figure 1 . In 43 patients, the therapy has to be discontinued due to adverse drug reactions while in 32 patients, the adverse drug reactions resolved over time or after the decrease in AZA dose. Adverse drug reactions in current and past AZA users are given in Table 2 .
Adverse drug reactions to azathioprine therapy according to TPMT genotype
In the next step we analyzed the infl uence of TPMT genotype on the incidence of adverse drug reactions. Patients with any TPMT *3 There was one patient homozygous for TPMT *3A genotype. In 1997, a rectovesical fi stula was diagnosed and azathioprine 50 mg was added to 5-ASA and corticosteroid regime. Two weeks after the onset of AZA therapy a severe pancytopenia developed with WBC 2.4x10 9 /L, Hb 97 g/L and platelets 147x10 9 /L. Azathioprine was stopped immediately and the pancytopenia resolved spontaneously within four weeks.
Clinical circumstances of adverse drug reactions to AZA with respect to TPMT genotype
Next we analyzed the difference among patients with TPMT wild type and *3 mutations with respect to the onset, AZA dose and severity of ADR. We analyzed the data separately for hematologic and non-hematologic ADRs (Tab. 4). In the hematologic ADR subgroup we observed a more severe myelotoxicity in a subgroup of patients with the TPMT mutations (mean WBC 2.0±0.8. 
Tab. 4. Studied clinical and laboratory parameters at the time of ADR in patients with myelotoxicity after AZA therapy.
When we analyzed the data on the time to onset of adverse drug reactions separately for hematologic and non-hematologic ADRs and TPMT genotype, we found no signifi cant difference in either subgroup. Myelotoxicity occurred within the fi rst year of therapy in all but 2 patients in the TPMT mutation subgroup (Fig. 2) . In the non-hematologic side effects subgroup, adverse drug reactions occurred in 25/30 patients within the fi rst three months of therapy.
The effect of mesalazine on the occurrence of side effects
All patients used mesalazine as 5-ASA medication. Data on concomitant use of mesalazine at the time of adverse drug reaction were available in 69/75 patients. Concomitant mesalazine use was recorded in 51/69 (73.9 %) patients at the time of adverse drug reaction. Concomitant mesalazine use among patients currently on azathioprine (and no ADRs) was 112/169 (66.3 %), p=n.s. There was also no difference in the presence of particular side effect, severity of bone marrow suppression, and studied laboratory parameters among concomitant mesalazine users and non-users at the time of ADR
Discussion
In our retrospective multicenter study we analyzed the impact of TMPT genotype on the incidence and characteristics of adverse drug reactions in a Slovak cohort of 220 IBD patients treated with azathioprine.
Limitations of the study
There are two sources of potential bias in our study that we are aware of. Firstly, all participating centers are tertiary referral IBD centers. There are many patients referred to these centers for the application of biological therapy, including those with AZA intolerance. This presents a potential selection bias which can therefore expectedly increase the incidence of adverse reactions in our cohort compared to general IBD population. On the other hand, we were able to analyze a larger subgroup of patients with ADRs in our cohort. We do not expect the potential referral bias to have other effect than that of increased incidence of ADRs in our cohort, thus the proportion of particular ADRs and the associations with TPMT genotype are not affected.
The retrospective design of our study is the second general limitation. The recall and retrieval bias potentially limits especially the incidence of mild adverse drug reactions (e.g. mild nausea) and studied circumstances of AZA adverse drug reactions such as exact time to ADR, concomitant medication and laboratory results at the time of ADR etc. We tried to overcome this bias by careful inspection of physical as well as electronic patient data fi les including laboratory results. In case of referred patients (approximately 30% of the cohort), the referring physician was contacted and consulted if necessary.
Adverse drug reactions
In our study we observed a high incidence of ADRs to AZA therapy. Myelotoxicity was observed in 14.5 % of our patients, hepatotoxicity in 10.9 %, dyspepsia in 3.2 %, pancreatitis in 2.7 %, allergic reactions in 0.9 % and other in 1.8 %. Generally the reported total AZA toxicity in published studies is in a range of 10-20 % (19, 20) depending on the cohort of patients. Some authors however report up to 25 % frequency of myelotoxicity in AZA-treated patients (21) . We think however that the reason for the observed high frequency of ADRs in our cohort is the above discussed referral character of the participating IBD centers. Furthermore, in the participating IBD centers, the patients are meticulously monitored for ADRs after the initiation of AZA therapy including regular biochemistry monitoring (hepatic and pancreatic enzymes). This might also in part explain the relatively high frequency of hepatotoxicity in our cohort.
The problem of gastrointestinal ADRs (except for pancreatitis) can usually be overcome through switching from AZA to 6-MP or in selected cases to thioguanine (22) . Myelotoxicity is more diffi cult to address. It can be attempted to discontinue the drug administration and/or reduce the dose, however it is a risky approach and in many cases, thiopurines must be stopped.
Prevalence of TPMP
The frequency of patients with TPMT *3 mutation in our cohort was 6.8% including 13 /220 (6 %) TPMT *3A heterozygote patients, 1/220 (0.4 %) TPMT *3C heterozygote, and 1/220 (0.4 %) TPMT *3A homozygote. That corresponds to allele frequencies of 3.4 % for TPMT *3A allele and 0.2 % for the TPMT *3C allele. This is in accordance with the allele frequencies found in most studies in Caucasians. The allele frequencies of common TPMT mutations in central and eastern European countries are in a range of 3.2-4.9 % (23-27). In a Czech study on 398 IBD patients and 300 healthy controls, the frequencies of TPMT*2, TPMT*3A, TPMT*3B, and TPMT*3C were 0.1 %, 4.3 %, 0.1 %, and 0.4 %, respectively (23) . In a Polish study on 358 healthy subjects, the allelic frequencies were 0.4 % for TPMT*2, 2.7 % for TPMT*3A, and 0.1 % for TPMT*3C, respectively. The TPMT*3B allele was not found in the studied population (24) .
Association of TPMT and adverse drug reactions
In our study we observed a strong association between TPMT polymorphisms and hematologic adverse drug reactions. There was however no association with gastrointestinal or any other adverse drug reactions. Bone marrow suppression occurred in 73 % of patients with variant-type TPMT and only in 10 % of TPMT wild-type patients (p=1.10 -6 ). There is no doubt about the association of homozygote TPMT *3A genotype with severe bone marrow suppression (28) . However the association of heterozygotes with intermediate TPMT activity and myelotoxicity was not clear-cut. There were several studies that suggested no signifi cant association between TPMT and myelotoxicity in heterozygotes (15, 29, 30 Recently there were two meta-analyses of TPMT status and hematologic toxicity published. Dong et al published a meta-analysis of nine studies performed in IBD patients (32) . Five of the studies in the meta-analysis showed an association between TPMT mutations and myelotoxicity while four failed to demonstrate this association. The pooled results showed a signifi cant association between TPMT genotype and myelotoxicity. In the pooled data 23 /110 (20.9 %), patients with TPMT variant genotype but only 77/1309 (5.9 %) patients with wild-type genotype experienced bone marrow toxicity giving a pooled OR=5.93 (95% CI 2.96-11.88), p= 0.00001. No association was confi rmed for hepatotoxicity or pancreatitis. The frequency of myelotoxicity among TPMT heterozygotes in analysed studies ranged from 0-60%. In another more specifi c meta-analysis by Higgs et al, only patients with intermediate TPMT activity were compared to wild-type TPMT patients (28) . The study was not limited to certain disease and included 67 mostly retrospective studies. The odds ratio for developing leukopenia for patients with intermediate TPMT activity compared to the normal TPMT patients was 4.19 (95% CI: 3.20-5.48).
TPMT and dose, time to AE, severity, 5-ASA
In our study the patients with TPMT *3 mutation developed a significantly more severe bone marrow suppression (WBC 2.0±0.8.10 9 /L) as compared with the patients with wild type TPMT (WBC 2.5±0.6.10 9 /L; p=0.007). There are few studies, which address the issue of adjusting AZA dose in patients with TPMP mutation. In a study with 71 patients by Regueiro et al, the incidence of ADRs was recorded after starting AZA over a period of one year including 8 patients with intermediate TPMT activity (33) . Seven patients were started on 1 to 1.5 mg/kg/d of AZA, and one did not receive treatment. None of the TPMT intermediate patients receiving a reduced dose of AZA, developed leukopenia (defi ned as less than 3,000/mm 3 ). In our study we have not observed any clinically signifi cant interaction between AZA and 5-ASA in terms of the incidence of ADRs. Earlier studies suggested an inhibitory effect of sulfasalazine and TPMT (34) . Newer studies suggest no signifi cant ex vivo effect of now widely used mesalazine (35) . Gilissen et al studied a small cohort of 17 patients on concomitant 6-MP (0.78 mg/kg/day) and mesalazine (3g/day) therapy (36) . After mesalazine discontinuation, mean tioguanine levels changed signifi cantly from 262 to 209 pmol/8 × 10
8 red blood cells, increasing to 270 after reintroduction. Leucocyte counts however were stable. In a clinical study on 186 IBD patients, concurrent use of 5-aminosalicylate drugs did not reduce the relapse rates of infl ammatory bowel disease in patients established on azathioprine therapy (37) . Furthermore the use of 5-aminosalicylate drugs did not lead to any increase in discontinuation of azathioprine due to adverse drug reactions.
There is an ongoing discussion, whether to perform TPMT genotyping and/or measurement of TPMT activity before initiating an AZA therapy in IBD patients. The American Gastroenterological Association issued a medical position statement on TPMT genotyping while refl ecting the current FDA recommendation that in an effort to detect individuals with low enzyme activity, The patients should have their TPMT genotype or phenotype assessed before the initiation of AZA therapy (4) . The European Crohn's and Colitis Organisation (ECCO) recommends not to yet consider TPMT status determination as a pre-requisite to AZA or 6-MP therapy (5).
Our results suggest that the myelotoxocity could be prevented in around 5 % of our patients (73 % positive predictive value in 6.8 % TPMT variant patients of the cohort). This includes patients developing more severe bi-or pancytopenia representing 1.4 % of genotyped patients. Considering the more conservative 20 % positive predictive value of TPMT heterozygous status for myelotoxicity observed in meta-analysis by Dong et al, it could still be prevented in about 1.5 % of patients (32) . We believe this is an argument for TPMT genotyping or activity measurement in all IBD patients considered for AZA therapy. If the TPMT status determination is not routinely performed, it should be strongly considered at least in patients in whom bone marrow suppression can be potentially devastating such as in elderly, patients with known severe medical condition or patients with moderate to severely impaired renal function.
Conclusion
The prevalence of TPMT mutation in the Slovak population is comparable to other studies in Caucasians and led to bone marrow suppression in a signifi cant proportion of our patients. TPMT genotyping could have prevented myelotoxicity in about 5% of our patients. TPMT genotyping of activity measurement should be performed at least in high-risk subgroups of IBD patients in whom AZA therapy is considered.
